Inherited Retinal Diseases Overview, Patient Resources, and Clinical Trials - Part 1 - Post Test

Retinitis pigmentosa usually affects which cell type first?*
- A. Cones
- B. Rods
- C. RPE
- D. None of the above
Stargardt disease:*
- A. Only affects adults
- B. Is caused by mutations in RPE65
- C. Is caused by buildup of toxins in RPE cells
- D. Can be caused by one of seven genes
Antisense oligonucleotides are used in:*
- A. RNA therapies
- B. Gene augmentation/replacement
- C. Anti-VEGF injections
- D. None of the above
Gene augmentation/replacement trials are underway for:*
- A. Retinitis pigmentosa
- B. Choroideremia
- C. People with mutations in RPGR
- D. All of the above
Achromatopsia is a condition that causes:*
- A. Extreme light sensitivity
- B. Hearing loss
- C. Corneal abrasions
- D. Night blindness
A central scotoma is the hallmark of:*
- A. Retinitis pigmentosa
- B. Stargardt disease
- C. Choroideremia
- D. Usher syndrome
Patients registries for IRDs:*
- A. Always protect a patients’ privacy
- B. Help patients get on the radar of researchers and companies
- C. Are monitored by the FDA
- D. Limit the number of registrants
Emerging stem cell therapies for IRDs:*
- A. Can be designed to protect existing retinal cells
- B. Can be designed to replace lost retinal cells
- C. Are only injected subretinally
- D. a. and/or b.
Usher syndrome is:*
- A. Always inherited recessively
- B. A leading cause of combined hearing and vision loss
- C. Not easy to diagnose through genetic testing
- D. a. and b.
10) Which of the following are true?*
- A. Genetic testing provides a conclusive result in 60-70% of IRD cases
- B. If a patient has an IRD, it is almost certain one of their relatives has the condition
- C. Diabetes increases the risk of an IRD
- D. a. and c.

Inherited Retinal Diseases Overview, Patient Resources, and Clinical Trials – Part 1 – Post Test

FB-001 Post Test

Step 1 of 2

Inherited Retinal Diseases Overview, Patient Resources, and Clinical Trials – Part 1 – Post Test

FB-001 Post Test

Step 1 of 2

Join our newsletter